BCOV): Q1 EPS of -$0.02 beats by $0.03.Revenue of $32.89M (+5.8% Y/Y) beats by $0.84M.
Brightcove delivered first quarter results that exceeded our expectations from both a revenue and profitability perspective, said David Mendels, Chief Executive Officer of Brightcove (BCOV).
We remain on track to achieve our full year revenue and profitability targets, while generating accelerating revenue growth throughout the year and returning to non-GAAP profitability in the fourth quarter. We still have additional progress to make on our business transformation and operational execution in the coming quarters, which we believe will drive improved financial performance and ultimately significant value for our shareholders.
:AXTI): Q1 EPS of -$0.03 in-line.Revenue of $20.1M (+3.9% Y/Y) beats by $0.16M.
Management Qualitative Comments
"As we move into 2015, our goal is to take advantage of developing market conditions in our business," said Morris Young, chief executive officer. "Gallium arsenide has stabilized and addresses a market with numerous applications and dynamic opportunities. Indium phosphide is growing and we are investing in ways to capitalize on industry demand. Additionally, we see catalysts for growth this year in several of our target markets and believe that we continue to benefit from our unique vertical integration. In total, our diversified revenue base, solid competitive positioning and lower cost structure give us renewed optimism for our direction and prospects."
Headed South ? Uh, from 14.66 to 4, I'd say that ship has sailed. Like so many others in the oil related sector, it's a wait and see if they can maneuver through this over supply / price debacle.
Amarin finally receives Vascepa CRL from FDA • 10:16 AM
Douglas W. House, SA News Ed...
It took more than a year, but the FDA finally sends a Complete Response Letter (CRL) to Amarin (AMRN -5.1%) to address its supplemental New Drug Application (sNDA) for an expanded label for Vascepa (icosapent ethyl) to include use as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with mixed dyslipidemia (one or more lipid disorders) and triglyceride levels from 200 to 499 mg/dL (ANCHOR population). Vascepa is currently cleared as an adjunct to diet to reduce TG levels in adult patients with severe ( =500 mg/dL) hypertriglyceridemia. Vaccepa's current labeling remains unchanged.
The original PDUFA date for the sNDA was December 20, 2013. In October, the FDA rescinded the Special Protocol Assessment after its advisory committee voted 9-2 against the expanded indication citing the need for "more clinically relevant measures of efficacy."
In the CRL, the FDA acknowledged that Vascepa demonstrated a treatment effect compared to placebo in reducing TG levels in the ANCHOR study but stated that there are insufficient data at present that support a drug-induced change in TGs as a surrogate for reducing CV risk, the rationale for the use of Vascepa in the ANCHOR population. The FDA did not determine that the effects of Vascepa, which go beyond lowering TGs, would not actually reduce CV risk. Despite Amarin proposing alternative indications and disclaimers, the agency has decided not to approve the expanded indication.
The company, with the support of the FDA, intends to complete the 8,000 patient REDUCE-IT CV outcomes study, which is currently 93% enrolled. The independent Data Monitoring Committee is expected conduct an interim review of the data in 2016. The study is projected to be completed in 2017 with final results available and published in 2018.
Oh please, that is old news. Some broker messed up with a penny stock firm and was canned years ago.
This has relevance how ? Every firm on the street has had this happen. What else you got ?
bh, I agree totally. They are still off the big radar screen for some reason. Maybe they need to present
their case to analysts somewhere. Company is significantly undervalued. Exactly one year ago, somebody really liked them. Look at the chart. I wonder where those buyers went. Technically alone this should pop to 16 IMO.
No, not yet. Don't like it ? Sell and go away.
Achieved two new design wins with a large new data center OEM customer. Sales are expected to increase in the second half as all required DOCSIS 3.1 products become available. In total, they continue to expect their CATV revenue to grow more than 20% in 2015 compared with 2014. They expect Q1 revenue to be between $35.0 million to $36.5 million, representing 41% to 47% year-over-year growth.